We demonstrated that nanovehicles developed from phenylboronic acid‐functionalized polypeptides could enable nearly quantitative coencapsulation and triggered release of both BCL2 and MCL1 inhibitors for synergetic and potent therapy of AML. This evidence concerns the gene MCL1 and acute myeloid leukemia.